Navigation Links
Stereotaxis Receives $20 Million in Additional Loan Commitments
Date:2/7/2008

ST. LOUIS, Feb. 7 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today announced that it had obtained $20 million in one-year unsecured loan commitments from two current shareholders. In addition, the Company may extend the commitment for an additional 90 days, at its option. Funds drawn on the commitment would be subordinated to borrowings under its current bank facility. In consideration of providing the commitment, Stereotaxis agreed to grant to the investors common stock warrants, equal to 20% coverage of the commitment amount at an exercise price of $6.99 per share. Additional warrants equal to 5% coverage would be issuable if the Company exercised its 90-day extension.

"At year end 2007, the Company had approximately $24 million of cash and investments, including $5 million drawn on its working capital facility. Combined with and subject to the terms of the remaining un-drawn facility, this commitment provides Stereotaxis with up to approximately $60 million of liquidity, which we believe is sufficient to execute our growth strategy well into 2009," said Bevil Hogg, Chief Executive Officer.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

About Forward Looking Statements

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
2. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
3. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
4. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
5. MedApps Receives Prestigious Frost & Sullivan Award
6. IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price
7. Ludwig Institute for Cancer Research receives NHMRCs largest 2009 grant
8. Jacobs Receives Contract from Catholic Healthcare West to Assist Sequoia Hospital Expansion Program
9. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
10. Regions Hospital Receives National Quality Awards
11. Laser Energetics Receives a $550,000 Order for a Dental Laser System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... The successful implementation of “lean manufacturing” in various fields ... laboratories have different challenges compared to manufacturing environments. , In order to provide ... TOLEDO has developed the Lean Lab Checklist . This checklist will help users ...
(Date:5/31/2016)... ... May 31, 2016 , ... In ... can describe personality traits in humans. Using presidential candidate Donald Trump as an ... vitality. , “AstroNumerology is not about adding numbers up,” says Kalsi. “It ...
(Date:5/31/2016)... ... ... Phynd Technologies, Inc. announced recently the signing of three new hospitals: Meadows ... Center – Somers Point, NJ. The new clients range in bed size from 57 ... Phynd’s solution and its interoperability. , Houston Methodist is a leading academic medical center ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... Dr. Charles ... and Dentistry of New Jersey in the class of 1986, where he graduated in ... dentistry at his current location in Livingston since 1989. He has been a member ...
(Date:5/31/2016)... Washington, NY (PRWEB) , ... May 31, 2016 , ... ... other essential nutrients to on the go individuals and dedicated athletes, continues to transform ... , Loaded with whey, pea and milk protein, branched-chain amino acids (BCAA), alkaline ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... RnRMarketResearch.com adds "Asthma - Pipeline ... of Asthma therapy at various stages, therapeutics assessment by ... (RoA) and molecule type, along with latest updates, and ... players involved in the therapeutic development for Asthma and ... Complete report on H1 2016 pipeline review of Asthma ...
(Date:5/30/2016)... 2016 According to ... Market by Technology (Single-factor (Fingerprint, Face, Iris, ... (Workforce Management), End User (Hospitals, Healthcare Institutions) ... MarketsandMarkets, the market is projected to reach ... 1,182.6 Million by 2016, at a CAGR ...
(Date:5/30/2016)... May 30, 2016 The ... USD 7.3 billion by 2024, according to a ... increasing natality rate, the growing malnutrition coupled with ... and gastro-intestinal tract diseases are expected to boost ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
Breaking Medicine Technology: